Keytruda NSCLC Approval Will Test PD-L1 Expression
This article was originally published in The Pink Sheet Daily
Labeling is specific for those with PD-L1 expression as measured with a new companion diagnostic and does not reference data for PD-L1 negative patients.
You may also be interested in...
Q1 Earnings Preview: With the positive vote on its merger with Celgene behind it, Bristol now needs to focus on growing its immuno-oncology business, where several upcoming catalysts could bolster Opdivo.
FDA’s most recent accelerated approvals for Merck’s Keytruda call for confirmatory trials in a broader patient population than the approved indications, in the latest example of FDA’s growing comfort with multi-purpose confirmatory trials in the PD-1/PD-L1 inhibitor space.
Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.